title: Nebulized hypertonic saline containing hyaluronic acid improves tolerability in patients with cystic fibrosis and lung disease compared with nebulized hypertonic saline alone: a prospective, randomized, double-blind, controlled study.
abstract: BACKGROUND
  Hypertonic saline inhalation has been shown to be effective in patients with cystic fibrosis and lung disease. However, adverse events including marked airway narrowing are reported and a bronchodilator must be given before the administration of the product.
  
  
  METHODS
  We carried out a prospective, randomized, double-blind, parallel-group, controlled study of a hypertonic saline solution containing hyaluronic acid (Hyaneb) versus standard hypertonic saline therapy to assess whether the presence of hyaluronic acid would improve the tolerability of hypertonic saline.
  
  
  CONCLUSIONS
  The results showed that nebulized Hyaneb was more effective in reducing the need for β(2) bronchodilators and caused a significant reduction in the incidence of adverse effects compared with nebulized hypertonic saline solution alone. Its safety profile indicates that Hyaneb can be used for the treatment of lung disease in cystic fibrosis.
authors.affiliation: Ospedale dei Bambini 'Di Cristina' - Arnas Civico, U.O. II Pediatria per la Fibrosi Cistica (CRR) e le Malattie Respiratorie - Dcp/S. di Kartagener (CRR), Piazza Montalto , Palermo, Italy. marilufurnari@tin.it
authors.forename: Maria Lucia
authors.initials: ML
authors.lastname: Furnari
authors.forename: Lisa
authors.initials: L
authors.lastname: Termini
authors.forename: Gabriella
authors.initials: G
authors.lastname: Traverso
authors.forename: Stefania
authors.initials: S
authors.lastname: Barrale
authors.forename: Maria Rita
authors.initials: MR
authors.lastname: Bonaccorso
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Damiani
authors.forename: Caterina Lo
authors.initials: CL
authors.lastname: Piparo
authors.forename: Mirella
authors.initials: M
authors.lastname: Collura
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000503:physiopathology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008171:Lung Diseases / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D009330:Nebulizers and Vaporizers; D011446:Prospective Studies; D012462:Saline Solution, Hypertonic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D012462:Saline Solution, Hypertonic; D006820:Hyaluronic Acid